Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL330520 | 0.91 | HDAC8 (0.37) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL330519 | 0.91 | HDAC8 (0.37) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL3674630 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL1943013 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL13610589 | 0.84 | HDAC1 (0.37) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL10254350 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL17676680 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL15747003 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL13783718 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 | |
| SCHEMBL8026867 | 0.84 | HDAC1 (0.39) | HDAC1HDAC8CYP3A4HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | HDAC1 1450/4885HDAC8 2469/4885CYP3A4 544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.